STOCK TITAN

BriaCell Therapeutics Corp. - $BCTX STOCK NEWS

Welcome to our dedicated page for BriaCell Therapeutics news (Ticker: $BCTX), a resource for investors and traders seeking the latest updates and insights on BriaCell Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BriaCell Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BriaCell Therapeutics's position in the market.

Rhea-AI Summary

BriaCell Therapeutics has announced a clinical supply agreement with BeiGene to assess the safety and efficacy of BriaCell’s Bria-OTS™ immunotherapy in combination with BeiGene's anti-PD-1 antibody, tislelizumab, for treating advanced, heavily pretreated metastatic breast cancer. This Phase 1/2 trial will initially focus on Bria-OTS™ alone in breast cancer, expanding to a combination therapy with tislelizumab. BriaCell aims to extend this therapy to prostate and other cancers. The Bria-OTS™ platform builds on Bria-IMT™, which has shown benefits in patients with CNS metastases and resistance to checkpoint inhibitors and ADCs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
none
-
Rhea-AI Summary

BriaCell Therapeutics announced promising clinical data for its lead product candidate, Bria-IMT™, at the ASCO 2024 Annual Meeting. Key results include a median progression-free survival (PFS) of 4.1 months in ADC-resistant advanced breast cancer patients, which is double the PFS of patients in similar studies. The clinical benefit rate was 55% across HR+, HER2+, and TNBC disease types. Additionally, the therapy achieved an 83% intracranial objective response rate in patients with CNS metastases. The treatment was well-tolerated with no related discontinuations or cases of interstitial lung disease. These findings will be presented through various sessions during the ASCO event held from May 31 to June 4, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
Rhea-AI Summary

BriaCell Therapeutics, a clinical-stage biotech firm, has closed a $5.0 million registered direct offering with institutional and existing investors, including a director. The offering involves the sale of 2,402,935 common shares and warrants, with each unit priced at $2.00 to $2.215. The proceeds will fund working capital, R&D, a Phase 3 breast cancer study, and legal costs. A.G.P./Alliance Global Partners acted as the sole placement agent. The offering has been conducted under an existing shelf registration statement filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.19%
Tags
Rhea-AI Summary

BriaCell Therapeutics announced a $5.0 million registered direct offering, involving the sale of 2,402,935 common shares or pre-funded warrants and warrants to institutional investors and a director. The shares are priced at $2.00 each for institutional investors and $2.215 for the director, with warrants exercisable at $2.11 within six months and expiring in five years. The proceeds will support working capital, R&D, including a Phase 3 study in advanced breast cancer, and potential share repurchases. The offering closes around May 17, 2024, subject to customary conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.75%
Tags
-
Rhea-AI Summary
BriaCell Therapeutics Corp. announces oral and poster presentations at ASCO 2024 by Mayo Clinic Professor Saranya Chumsri on clinical data of Bria-IMT™ in advanced metastatic breast cancer. Two posters feature collaborations with prominent medical professionals in pivotal Phase 3 study and clinical data of Bria-IMT™ in patients who failed ADCs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
none
-
Rhea-AI Summary
BriaCell Therapeutics Corp. reports strong anti-cancer activity of Bria-OTS+™ and Bria-PROS+™ immunotherapies in breast and prostate cancer patients based on preclinical data presented at AACR 2024. The novel mechanisms of action show enhanced immune responses and activation of key immune system components, potentially leading to potent and long-lasting anti-cancer effects. The next-generation platforms aim to provide personalized, off-the-shelf, and ready-to-use therapies with improved efficacy and safety profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
none
Rhea-AI Summary
BriaCell Therapeutics Corp. presents positive clinical data for Bria-IMT™ at AACR Annual Meeting, showcasing significant potential in managing CNS metastatic disease in advanced breast cancer. With a PFS of 4.2 months, clinical benefit rate of 56%, and 71% iORR, the findings reinforce the clinical efficacy of Bria-IMT™ in patients resistant to ADCs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
none
-
Rhea-AI Summary
BriaCell Therapeutics Corp. signs an agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ and Bria-PROS+, its novel personalized cancer vaccines. The collaboration with Dr. Paula Pohlmann from MD Anderson Cancer Center marks a significant milestone in BriaCell's mission to revolutionize cancer care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.05%
Tags
-
Rhea-AI Summary
BriaCell Therapeutics Corp. announces the presentation of three posters at the 2024 AACR Annual Meeting, showcasing the efficacy and safety of their immunotherapies in cancer care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.24%
Tags
conferences clinical trial
Rhea-AI Summary
BriaCell Therapeutics Corp. updates on the investigation of alleged illegal trading activity of its securities by filing complaints with FINRA and CIRO after identifying significant settlement share imbalances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.57%
Tags
none
BriaCell Therapeutics Corp.

Nasdaq:BCTX

BCTX Rankings

BCTX Stock Data

25.19M
11.64M
12.27%
15.46%
4.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WEST VANCOUVER

About BCTX

briacell therapeutics corp immunotherapy approaches to cancer management briacell is a los angeles headquartered biotechnology company focused on immunotherapy treatments for cancer management. to date, the company has been successful in developing its patented "briavax" vaccine and implementing two compelling fda phase-i studies with late-stage breast cancer patients, demonstrating unique and unprecedented results. briacell is focused on aggressively moving towards launching its next clinical trial, a phase-i/ii study, in order to apply its vaccine to a larger number of breast cancer patients and effectively progress its technology along the value chain. while the current corporate focus is breast cancer, the company has an eye towards potentially applying its vaccine technology to certain other cancer types as well.